API
BMRN icon

Advisor Partners II’s BioMarin Pharmaceuticals BMRN Stock Holding History

Advisor Partners II’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$348K Buy
3,933
+1,499
+62% +$133K 0.01% 879
2023
Q2 		$211K Buy
+2,434
New +$229K 0.01% 980

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Advisor Partners II's BMRN Position: Q3 2023 in Review

Advisor Partners II increased its BioMarin Pharmaceuticals (BMRN) stake by 62% in Q3 2023, buying an estimated $133K and bringing the position to 3,933 shares worth $348K. The position accounts for 0.01% of the portfolio, ranked #879.

Advisor Partners II first reported a position in BMRN in Q2 2023 and has held it in 2 quarters since. 519 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

  • Advisor Partners II held 3,933 shares of BioMarin Pharmaceuticals worth $348K as of Q3 2023.
  • Advisor Partners II bought 1,499 BioMarin Pharmaceuticals shares in Q3 2023, an estimated $133K.
  • BioMarin Pharmaceuticals made up 0.01% of Advisor Partners II's portfolio in Q3 2023, its #879 holding.
  • Advisor Partners II first reported a position in BioMarin Pharmaceuticals in Q2 2023 and has held it in 2 quarters since.
  • 519 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on Advisor Partners II's 13F filing for Q3 2023, filed 26 Oct 2023.